Form 4: Supernus Pharmaceuticals CEO Jack A. Khattar Reports Stock Transactions
SEC Form 4 Filing
Jack A. Khattar, CEO of Supernus Pharmaceuticals, reports the acquisition and disposal of company stock related to performance share units.
Summary
- On September 3, 2024, Jack A. Khattar, the President and CEO of Supernus Pharmaceuticals, engaged in transactions involving the company's common stock.
- Khattar acquired 21,000 shares of common stock upon the settlement of performance share units.
- Simultaneously, 10,045 shares were withheld by the company to satisfy tax obligations related to the vesting of these units at a price of $34.9 per share.
- Following these transactions, Khattar directly owns 926,172 shares and indirectly owns 1,022,450 shares through the KBT Trust.
Sentiment
Score: 6
Explanation: The document is a standard SEC filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but the vesting of performance share units suggests the achievement of certain goals.
Positives
- The vesting of performance share units suggests the achievement of certain performance objectives.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. This filing indicates transactions related to previously awarded performance-based compensation.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership by a key executive.
- Employees may view the vesting of performance share units positively, as it reflects the achievement of company goals.
Key Dates
| Date | Description |
|---|---|
| February 23, 2023 | Reporting Person was awarded Performance Share Units |
| June 12, 2023 | Objectives were established for Performance Share Units |
| September 03, 2024 | Date of stock transactions (acquisition and disposal related to performance share units). |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.